Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032571 | 0.88 | CYP1A2 (0.41) | KCNA5KCNH2CYP2D6CYP1A2CYP19A1 | |
| SCHEMBL7033054 | 0.86 | LMNA (0.41) | KCNH2CYP2D6CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL7028844 | 0.85 | KDM4E (0.43) | KCNH2CYP2D6CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL7026422 | 0.85 | KDM4E (0.43) | KCNH2CYP2D6CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL7034408 | 0.85 | KDM4E (0.43) | KCNH2CYP2D6CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL7157608 | 0.85 | KDM4E (0.43) | KCNH2CYP2D6CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL7031343 | 0.80 | LMNA (0.40) | CYP2D6CYP1A2CYP2C19KDM4ELMNA | |
| SCHEMBL7028638 | 0.80 | KCNA5 (0.33) | KCNA5KCNH2CYP2D6CYP1A2KCNE1 | |
| SCHEMBL7032030 | 0.79 | RAB9A (0.40) | KDM4ESMN1; SMN2NPC1RAB9AALOX12 | |
| SCHEMBL7030726 | 0.79 | NPC1 (0.36) | CYP1A2KDM4ELMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139600-A1 | 2-pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL CO., LTD. | 2003-07-24 | — | — | US | disclosed |
| US-6548673-B1 | Alkylation using transition metal complex catalyst; purified by acid/base extraction | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-15 | — | — | US | disclosed |
| US-6531602-B2 | Desilylation of a 2-pyridylsilane to form an alcohol | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-11 | — | — | US | disclosed |
| US-20020165397-A1 | 2-Pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL CO., LTD. | 2002-11-07 | — | — | US | disclosed |
| EP-1035125-A2 | 2-Pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165397-A1 | 2-Pyridylsilane, processes for producing and using the same | H1-0, RIOK2, H1-4 | KCNA5 333/4885KCNH2 60/4885CYP2D6 1375/4885 |
| US-20030139600-A1 | 2-pyridylsilane, processes for producing and using the same | H1-0, H1-4, H1-2 | KCNA5 359/4885KCNH2 61/4885CYP2D6 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.